Financial highlights 2022 total turnover of €18 million driven by strategic partnerships with pharmaceutical companies. €25.6 million available cash as of December 31st 2022, including
OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders' Meeting
94th Vifor Pharma Group Annual General MeetingAD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LRShareholders agreed to the Board of Directors’ recommendations for all proposed resolutionsDividend of CHF 2.00 approvedAll Board members re-elected and Conditional Board of Directors appointed, effective as from the date o.